Literature DB >> 22893608

Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner.

Laura R Bohrer1, Kathryn L Schwertfeger.   

Abstract

Infiltration of immune cells, specifically macrophages, into the tumor microenvironment has been linked to increased mammary tumor formation and progression. Activation of growth factor receptor signaling pathways within mammary epithelial cells, such as the fibroblast growth factor receptor 1 (FGFR1) pathway, induces recruitment of macrophages to the mammary epithelium. These macrophages promote increased epithelial cell proliferation and angiogenesis. However, the specific mechanisms by which these macrophages are regulated by the preneoplastic epithelial cells and the mechanisms of action of the macrophages within the developing FGFR1-driven tumor microenvironment remain unknown. In this study, we show that activation of inducible FGFR1 in mammary glands leads to decreased activity of the TGFβ/Smad3 pathway in macrophages associated with early stage lesions. Further studies show that macrophages have increased expression of inflammatory chemokines that bind Cxcr2 following exposure to conditioned media from mammary epithelial and tumor cells in which the FGF pathway had been activated. The increase in these ligands is inhibited following activation of the TGFβ pathway, suggesting that decreased TGFβ signaling contributes to the upregulation of these chemokines. Using coculture studies, we further show that macrophages are capable of promoting epithelial and tumor cell migration and invasion through activation of Cxcr2. These results indicate that macrophage-derived Cxcr2 ligands may be important for promoting mammary tumor formation regulated by FGFR signaling. Furthermore, these results suggest that targeting Cxcr2 may represent a novel therapeutic strategy for breast cancers that are associated with high levels of infiltrating macrophages.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22893608      PMCID: PMC3553584          DOI: 10.1158/1541-7786.MCR-12-0275

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  42 in total

Review 1.  TGF-beta signaling in mammary gland development and tumorigenesis.

Authors:  L M Wakefield; E Piek; E P Böttinger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 3.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

4.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).

Authors:  Subhra K Biswas; Lisa Gangi; Saki Paul; Tiziana Schioppa; Alessandra Saccani; Marina Sironi; Barbara Bottazzi; Andrea Doni; Bronte Vincenzo; Fabio Pasqualini; Luca Vago; Manuela Nebuloni; Alberto Mantovani; Antonio Sica
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

5.  Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3.

Authors:  F Werner; M K Jain; M W Feinberg; N E Sibinga; A Pellacani; P Wiesel; M T Chin; J N Topper; M A Perrella; M E Lee
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

Review 6.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

7.  Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.

Authors:  Kaouther Snoussi; Wijden Mahfoudh; Noureddine Bouaouina; Meriem Fekih; Hedi Khairi; Ahmed N Helal; Lotfi Chouchane
Journal:  BMC Cancer       Date:  2010-06-12       Impact factor: 4.430

Review 8.  Transforming growth factor-beta regulation of immune responses.

Authors:  Ming O Li; Yisong Y Wan; Shomyseh Sanjabi; Anna-Karin L Robertson; Richard A Flavell
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.

Authors:  Ariane Freund; Corine Chauveau; Jean-Paul Brouillet; Annick Lucas; Matthieu Lacroix; Anne Licznar; Françoise Vignon; Gwendal Lazennec
Journal:  Oncogene       Date:  2003-01-16       Impact factor: 9.867

10.  Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis.

Authors:  Johanna R Reed; Ronald P Leon; Majken K Hall; Kathryn L Schwertfeger
Journal:  Breast Cancer Res       Date:  2009-04-24       Impact factor: 6.466

View more
  38 in total

1.  CXCR2 and its related ligands play a novel role in supporting the pluripotency and proliferation of human pluripotent stem cells.

Authors:  Ji-Hye Jung; Seung Jin Lee; JiHea Kim; SongHee Lee; Hwa-Jung Sung; Jungsuk An; Yong Park; Byung Soo Kim
Journal:  Stem Cells Dev       Date:  2014-12-23       Impact factor: 3.272

2.  The FGF/FGFR axis as a therapeutic target in breast cancer.

Authors:  Nicholas Brady; Polly Chuntova; Lindsey K Bade; Kathryn L Schwertfeger
Journal:  Expert Rev Endocrinol Metab       Date:  2013-07

3.  Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages.

Authors:  Brian J Girard; Todd P Knutson; Bethanie Kuker; Laura McDowell; Kathryn L Schwertfeger; Julie H Ostrander
Journal:  J Biol Chem       Date:  2016-11-23       Impact factor: 5.157

4.  JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors.

Authors:  Emily A Irey; Chelsea M Lassiter; Nicholas J Brady; Pavlina Chuntova; Ying Wang; Todd P Knutson; Christine Henzler; Thomas S Chaffee; Rachel I Vogel; Andrew C Nelson; Michael A Farrar; Kathryn L Schwertfeger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-30       Impact factor: 11.205

Review 5.  In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.

Authors:  Ethan J Brock; Kyungmin Ji; Seema Shah; Raymond R Mattingly; Bonnie F Sloane
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-28       Impact factor: 2.673

Review 6.  Vicious cycle of TGF-β signaling in tumor progression and metastasis.

Authors:  Qiang Zhang; Nengwang Yu; Chung Lee
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

Review 7.  Implications of non-canonical G-protein signaling for the immune system.

Authors:  Cédric Boularan; John H Kehrl
Journal:  Cell Signal       Date:  2014-02-28       Impact factor: 4.315

Review 8.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

9.  Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation.

Authors:  Laura R Bohrer; Pavlina Chuntova; Lindsey K Bade; Thomas C Beadnell; Ronald P Leon; Nicholas J Brady; Yungil Ryu; Jodi E Goldberg; Stephen C Schmechel; Joseph S Koopmeiners; James B McCarthy; Kathryn L Schwertfeger
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

Review 10.  Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.

Authors:  Andrew C Nelson; Heather L Machado; Kathryn L Schwertfeger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-08-31       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.